Skip to main content
Cutia Therapeutics logo

Cutia Therapeutics — Investor Relations & Filings

Ticker · 2487 HKEX Manufacturing
Open in API
Filings indexed 176 across all filing types
Latest filing 2025-12-30 Board/Management Inform…
Country HK Hong Kong
Listing HKEX 2487

About Cutia Therapeutics

http://www.cutiatx.com

Cutia Therapeutics is an R&D-driven biopharmaceutical platform established in 2019, specializing in the research, development, manufacture, and commercialization of dermatological treatments. The company is dedicated to providing a comprehensive suite of innovative, safe, and effective solutions for patients and consumers. Its core therapeutic focus areas include the management of localized adipose accumulation and various scalp diseases. As a dermatology-focused entity, Cutia maintains a dedicated pipeline emphasizing novel candidates, including those targeting the Immune System domain.

Recent filings

Filing Released Lang Actions
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 1% confidence The document is titled 'LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS' and provides a breakdown of the board members, their classifications (Executive, Non-executive, Independent), and their committee memberships. This type of disclosure is standard corporate governance documentation regarding board composition and does not fit into specific financial reporting categories like 10-K or ER. Since it details the structure of the board and its committees, it falls under Governance Information.
2025-12-30 English
CHANGE OF NON-EXECUTIVE DIRECTOR
Board/Management Information Classification · 1% confidence The document is an official announcement from Cutia Therapeutics regarding the resignation of one non-executive director and the appointment of a new non-executive director. This content directly matches the definition for 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management.
2025-12-30 English
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, including share issues, treasury shares, and share options. It does not fit into specific categories like 'Annual Report' or 'Earnings Release' but is a mandatory periodic regulatory filing. Therefore, it is classified as a Regulatory Filing (RNS).
2025-12-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for companies listed on the HKEX to report monthly movements in their securities, including share capital, issued shares, and treasury shares. Since this document reports on changes in share capital and issued shares, it falls under the category of share issues and capital changes.
2025-12-04 English
VOLUNTARY ANNOUNCEMENT - ABBREVIATED NEW DRUG APPLICATION FOR CU-40105 (SELF-DEVELOPED TOPICAL FINASTERIDE SPRAY) ACCEPTED BY THE NMPA
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by Cutia Therapeutics regarding the acceptance of an Abbreviated New Drug Application (ANDA) by the NMPA for a specific product (CU-40105). It does not fit into financial reporting categories like 10-K or IR, nor does it relate to dividends, board changes, or share transactions. As it is a general regulatory announcement regarding business operations and product development that does not fall into a more specific category, it is classified as a Regulatory Filing (RNS).
2025-11-18 English
VOLUNTARY ANNOUNCEMENT - POST-HOC ANALYSIS OF PHASE III CLINICAL TRIAL OF CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC ACCEPTED FOR ORAL PRESENTATION AT THE 20TH CDA ANNUAL MEETING
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by Cutia Therapeutics regarding the acceptance of a post-hoc analysis of a Phase III clinical trial for presentation at a medical conference. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a dividend or share-related notice. As it is a general corporate update regarding business/clinical advancement that does not fall into the other specialized categories, it is classified as a Regulatory Filing (RNS).
2025-11-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.